Pages that link to "Q54237890"
Jump to navigation
Jump to search
The following pages link to Efficacy of aerosolized tobramycin in patients with cystic fibrosis. (Q54237890):
Displaying 50 items.
- Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis (Q22306312) (← links)
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (Q24202283) (← links)
- Inhaled antibiotics for long-term therapy in cystic fibrosis (Q24235635) (← links)
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (Q24241270) (← links)
- Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Q24247996) (← links)
- Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient (Q26752680) (← links)
- Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis (Q26829604) (← links)
- Perioperative Antibiotics in Thoracic Surgery (Q26994980) (← links)
- Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy (Q27014993) (← links)
- Fundamentals of aerosol therapy in critical care (Q28068836) (← links)
- Household solid fuel use and pulmonary function in an urban population in Shanghai, China (Q28384445) (← links)
- Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study (Q28388812) (← links)
- Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study (Q30442057) (← links)
- Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients (Q31802549) (← links)
- A Comparison of the Availability of Tobramycin for Inhalation From Vented vs Unvented Nebulizers (Q32066869) (← links)
- Inhaled antibiotics for lower airway infections. (Q33640488) (← links)
- Current concepts in the management of paediatric rhinosinusitis (Q33643495) (← links)
- Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies (Q33664918) (← links)
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. (Q33725822) (← links)
- Inhaled Antibiotic Therapy in Chronic Respiratory Diseases (Q33755342) (← links)
- Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks (Q33775986) (← links)
- Minimisation of aminoglycoside toxicity in patients with cystic fibrosis (Q33775991) (← links)
- Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment (Q33824149) (← links)
- Cystic fibrosis--an Indian perspective on recent advances in diagnosis and management (Q33929227) (← links)
- Global problem of drug-induced hearing loss (Q33936855) (← links)
- Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa (Q34004443) (← links)
- Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis (Q34111815) (← links)
- Breath sulfides and pulmonary function in cystic fibrosis (Q34116010) (← links)
- Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth (Q34167016) (← links)
- Cystic fibrosis in adults. From researcher to practitioner. (Q34183284) (← links)
- Antibacterial treatment of invasive mechanical ventilation-associated pneumonia (Q34218964) (← links)
- Inflammation and cystic fibrosis pulmonary disease (Q34249405) (← links)
- Pseudomonal infection in cystic fibrosis: the battle continues (Q34358536) (← links)
- The role of nebulized antibiotics in treating serious respiratory infections (Q34393840) (← links)
- Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics (Q34437719) (← links)
- Pulmonary Administration of Gentamicin During Liquid Ventilation in a Newborn Lamb Lung Injury Model (Q34444178) (← links)
- Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis (Q34491552) (← links)
- The rationale for aerosolized antibiotics (Q34566912) (← links)
- Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis (Q34570439) (← links)
- Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007 (Q34610291) (← links)
- Nebulized antibiotics in cystic fibrosis (Q34706830) (← links)
- Iseganan HCl: a novel antimicrobial agent (Q34768583) (← links)
- Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin (Q35111428) (← links)
- Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. (Q35131613) (← links)
- Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation (Q35259843) (← links)
- Improvement of nebulised antibiotic delivery in cystic fibrosis (Q35262999) (← links)
- Lung infections. 3. Pseudomonas aeruginosa and other related species (Q35532283) (← links)
- Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis (Q35532709) (← links)
- New medical management techniques for acute exacerbations of chronic rhinosinusitis (Q35545989) (← links)
- Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis (Q35557791) (← links)